<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方Info | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-17T20:26:02+08:00</updated>
  <subtitle>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>补体C3抑制剂上市申请获FDA优先审评！挑战40亿美元重磅药物依库珠单抗</title>
    <updated>2020-11-17T17:52:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/-CMKelfzaL6z0ncufnknUQ</id>
    <link href="https://mp.weixin.qq.com/s/-CMKelfzaL6z0ncufnknUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>南京圣和1类新药「和乐布韦」申报上市</title>
    <updated>2020-11-17T17:52:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-17:/s/a4CyRFLnvwsR3ajnj_LhrA</id>
    <link href="https://mp.weixin.qq.com/s/a4CyRFLnvwsR3ajnj_LhrA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州预计2021H1完成科创板IPO</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/5vl5PcahBkwawuVCEMHPIQ</id>
    <link href="https://mp.weixin.qq.com/s/5vl5PcahBkwawuVCEMHPIQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药明生物“1拆3”，市值超过药明康德</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/NIwudPMOzvIsBvCi98IftQ</id>
    <link href="https://mp.weixin.qq.com/s/NIwudPMOzvIsBvCi98IftQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>万春「普那布林」国际多中心III期临床试验获得阳性结果</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/TaCocRM9siP8bEAyb2_iEg</id>
    <link href="https://mp.weixin.qq.com/s/TaCocRM9siP8bEAyb2_iEg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>索马鲁肽联合cilofexo/firsocostat治疗NASH II期研究获积极结果</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/Fg9rPTST-VnKj3N6L1-iLQ</id>
    <link href="https://mp.weixin.qq.com/s/Fg9rPTST-VnKj3N6L1-iLQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州引进的HER2双抗获批临床</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/RVbmKQGKkdyPRGkA0iocpg</id>
    <link href="https://mp.weixin.qq.com/s/RVbmKQGKkdyPRGkA0iocpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国家医保局：三批国家集采共节约539亿；医保谈判药品扩大日期限制</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/BbSHmdhxsbsZzwt0GwUkMQ</id>
    <link href="https://mp.weixin.qq.com/s/BbSHmdhxsbsZzwt0GwUkMQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药魔方核心行业数据监测周报（11月7-13日）</title>
    <updated>2020-11-16T18:08:09+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/jNwVQ25neoWrXjKsqaEgHA</id>
    <link href="https://mp.weixin.qq.com/s/jNwVQ25neoWrXjKsqaEgHA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>扬子江「恩替卡韦口服溶液」即将获批</title>
    <updated>2020-11-15T17:57:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/1Dd3Et0LkTm3TXMWsWRyog</id>
    <link href="https://mp.weixin.qq.com/s/1Dd3Et0LkTm3TXMWsWRyog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>羧基麦芽糖铁可显著降低心衰再次住院风险</title>
    <updated>2020-11-15T17:57:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-15:/s/AHTX8_tv0_czw1amE-u6JQ</id>
    <link href="https://mp.weixin.qq.com/s/AHTX8_tv0_czw1amE-u6JQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>干货！信达生物公布研发管线最新进展（附PPT）</title>
    <updated>2020-11-14T18:14:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-14:/s/GCC_Q-PhtIuU2q5-0wHJ-w</id>
    <link href="https://mp.weixin.qq.com/s/GCC_Q-PhtIuU2q5-0wHJ-w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“拓益”争议背后的药品立项思考</title>
    <updated>2020-11-13T16:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/ozhjY8krrNwiE2723TlXzg</id>
    <link href="https://mp.weixin.qq.com/s/ozhjY8krrNwiE2723TlXzg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森「奥氮平口腔速溶膜」即将首家获批</title>
    <updated>2020-11-13T16:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/2tY2x8-QMooGpAUJeLS_6A</id>
    <link href="https://mp.weixin.qq.com/s/2tY2x8-QMooGpAUJeLS_6A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>礼来与万春医药子公司Seed Therapeutics达成7.9亿美元泛素化靶向蛋白质降解新药合作开发协议</title>
    <updated>2020-11-13T16:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/Z2Sl0HKWOpoh5lIeuA4n_w</id>
    <link href="https://mp.weixin.qq.com/s/Z2Sl0HKWOpoh5lIeuA4n_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康/安进first in class哮喘新药III期研究成功！</title>
    <updated>2020-11-13T16:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/ycPPvP5r7H8Dj1D3J2VUtA</id>
    <link href="https://mp.weixin.qq.com/s/ycPPvP5r7H8Dj1D3J2VUtA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正大天晴「泊马度胺胶囊」首仿获批！原研2020前3季度销售额超22亿美元</title>
    <updated>2020-11-12T16:09:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/nGz63ZIS2BmMo6gdwXJ2qg</id>
    <link href="https://mp.weixin.qq.com/s/nGz63ZIS2BmMo6gdwXJ2qg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>辉瑞CEO高位抛售60%个人股票</title>
    <updated>2020-11-12T16:09:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/q6zvNJHzLAB0oj6_Oi82MQ</id>
    <link href="https://mp.weixin.qq.com/s/q6zvNJHzLAB0oj6_Oi82MQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森药业「注射用替加环素」首家通过一致性评价</title>
    <updated>2020-11-12T16:09:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/Y7dR6rk2pXbarMQkt3PArA</id>
    <link href="https://mp.weixin.qq.com/s/Y7dR6rk2pXbarMQkt3PArA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Keytrud在华第7项适应症拟优先审评：一线结直肠癌</title>
    <updated>2020-11-12T16:09:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/P-uzt9QGLFwQTVIl_Ds4EQ</id>
    <link href="https://mp.weixin.qq.com/s/P-uzt9QGLFwQTVIl_Ds4EQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>